Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Purification
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This FACL6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 240-270 amino acids from the Central region of human FACL6.
ACSL6
Reactivity: Human
ELISA
Host: Rabbit
Polyclonal
HRP
Application Notes
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Restrictions
For Research Use only
Format
Liquid
Concentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
ACSL6
(Acyl-CoA Synthetase Long-Chain Family Member 6 (ACSL6))
FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL). It is characterized by a chromosomal translocation t(5,12)(q31,p13) that involves ETV6 and ACSL6.